Zogenix to Participate in the Global Mizuho Investor Conference 2017
29 nov. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4
28 nov. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting
21 nov. 2017 08h00 HE
|
Zogenix, Inc.
Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be...
Zogenix to Present at Stifel 2017 Healthcare Conference
14 nov. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
07 nov. 2017 16h01 HE
|
Zogenix, Inc.
During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndromeStudy 1 met primary endpoint of reduction in frequency of...
Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7
31 oct. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
19 oct. 2017 02h00 HE
|
Zogenix, Inc.
Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results...
Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
16 oct. 2017 08h00 HE
|
Zogenix, Inc.
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C. EMERYVILLE, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 oct. 2017 16h35 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Prices Public Offering of Common Stock
02 oct. 2017 20h05 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...